Organization | Consortium of Food Allergy Research

Consortium of Food Allergy Research Report issue

Academic/Hospital Phase 1 Phase 2

Founded: McLean Virginia United States (2005)

Organization Overview

First Clinical Trial

2007

NCT00461097

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2013

Timeline

NOW

Now

Active Ingredients

Drugs in Phase 2 Trials (5)

baked egg (1 trial)

glycerinated peanut allergenic extract (1 trial)

peanut allergen (1 trial)

vitamin d3 (1 trial)

Drugs in Phase 1 Trials (1)

e. coli-encapsulated, recombinant modified peanut proteins ara h 1, ara h 2, and ara h 3 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Dermatitis (Phase 2)

Dermatitis, Atopic (Phase 2)

Eczema (Phase 2)

Food Hypersensitivity (Phase 2)

Hypersensitivity (Phase 2)

Hypersensitivity, Immediate (Phase 2)

Peanut Hypersensitivity (Phase 2)

Psoriasis (Phase 2)

Overview

Highest Phase: Phase 2
# of Trials: 6
# of Trial APIs: 6